Synthetic hexapeptide GH secretagogue that strongly stimulates growth hormone release and appetite via the ghrelin receptor.
Last Updated: May 2026
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide ghrelin receptor agonist that stimulates growth hormone release and produces significant appetite stimulation — the latter making it distinctive among GHRPs and clinically interesting for cachexia research. It is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.
GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) that binds the ghrelin receptor (GHS-R1a) on both pituitary somatotrophs (producing GH release) and hypothalamic neurons in the arcuate nucleus (producing appetite stimulation). The dual effect distinguishes GHRP-6 from more selective GHRPs like ipamorelin (which avoids the appetite effect) and GHRP-2 (which has only mild appetite effects). Half-life is approximately 60 minutes. Evidence level: Human PK and Phase 1/2 (cachexia indications); no Phase 3 approval.
GHRP-6 was the first orally-active GH-releasing hexapeptide and the earliest in the GHRP class to reach clinical research. Phase 1/2 trials have explored GHRP-6 for cancer cachexia, anorexia, and post-gastric-surgery weight recovery — the appetite-stimulation profile is therapeutically interesting in wasting conditions. No Phase 3 efficacy approval has been achieved. Human PK studies confirm reliable dose-dependent GH and IGF-1 elevation with substantial appetite increase. Evidence level: Phase 1/2 human (cachexia indications); no Phase 3 approval.
GHRP-6 is the appetite-stimulation GHRP — same ghrelin-receptor mechanism as ipamorelin and GHRP-2 but with substantially greater hypothalamic appetite-receptor engagement. The appetite effect is the differentiating feature.
| GHS peptide | GH-release strength | Appetite stimulation | Use case context |
|---|---|---|---|
| Ipamorelin | Moderate | Minimal | Clean GH research |
| GHRP-2 | Strong | Mild | Diagnostic (Japan) |
| GHRP-6 | Strong | Significant (hunger) | Cachexia / appetite research |
| Hexarelin | Strongest | Mild | Cardiac research |
The most prominent GHRP-6 side effect is appetite stimulation, which is dose-related and pronounced. Beyond appetite, mild cortisol and prolactin elevation occurs, along with injection-site reactions and occasional transient flushing. The appetite effect is the primary clinical and research signal — buyers seeking GH-release effects without significant hunger generally choose ipamorelin or GHRP-2 instead. Evidence level: Phase 1/2 human safety; long-term unestablished.
GHRP-6 is not approved for any medical indication anywhere in the world as of May 2026. Phase 1/2 work in cachexia indications has not advanced to Phase 3 approval. It is sold strictly as a research-use-only compound by third-party laboratories. Regulatory context in are peptides legal regulatory status by country.
GHRP-6 synthesis is mature and widely distributed in the research-grade market, but identity verification matters because related hexapeptide GHS compounds — GHRP-2, hexarelin — can be mislabeled. Independent HPLC purity testing and mass spectrometry identity confirmation (expected MW 873.0 Da) are the meaningful purity signals. Guidance in how-to-test-peptides hub.
Peptigrity purchases GHRP-6 vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
GHRP-6 binds the ghrelin receptor in the hypothalamic arcuate nucleus, which is the brain region that mediates the appetite-stimulating effects of endogenous ghrelin. More selective GHRPs like ipamorelin avoid this hypothalamic engagement and don't produce the same hunger effect. The appetite effect is a function of receptor binding profile, not a side effect that can be dose-titrated away.
GHRP-6 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.
Both are ghrelin-receptor agonists that stimulate GH release, but ipamorelin is much more selective — it produces minimal cortisol/prolactin effects and essentially no appetite stimulation. GHRP-6 produces substantial hunger. Buyers seeking GH-release effects without appetite stimulation typically prefer ipamorelin.
Yes. GHRP-6 and other GHRPs are on the WADA Prohibited List (Section S2 — Peptide Hormones). For drug-testing context, see do peptides show up on drug tests.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW 873.0 Da). Mass spec distinguishes GHRP-6 from related hexapeptide GHS compounds. COA interpretation in red flags in peptide certificates of analysis.
No. GHRP-6 is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. GHRP-6 is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.